A recently published study demonstrates that sarilumab improves patient-reported outcomes in patients with rheumatoid arthritis who did not achieve adequate response with, or who were intolerant to, anti-tumor necrosis factor (anti-TNF) agents.
A recently published study demonstrates that sarilumab improves patient-reported outcomes (PROs) in patients with rheumatoid arthritis (RA) who did not achieve adequate response with, or who were intolerant to, anti-tumor necrosis factor (anti-TNF) agents.
Vibeke Strand, MD, and her coauthors, in a study sponsored by Sanofi and Regeneron, evaluated the effects of the monoclonal antibody administered together with conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) based on PROs in the TARGET trial.
The authors note that PROs are important supplemental endpoints that can help in evaluating responses to treatment for RA. While clinical measures of RA, including the American College of Rheumatology (ACR) response criteria, include PROs, such measures rarely assess fatigue, ability to work, health-related quality of life, or health status.
In the TARGET trial, which included the assessment of PROs, 546 adults with moderate to severe RA who did not respond adequately to, or did not tolerate, anti-TNF treatments were randomized to receive placebo, 150 mg of sarilumab, or 200 mg of sarilumab every 2 weeks together with csDMARDs. The PROs addressed in the study included measures of pain, fatigue, function, participation, and health status. The methods used to assess these areas included:
Changes from baseline at weeks 12 and 24 were analyzed using a mixed model for repeated measures that tested the least square mean (LSM) changes from baseline, between each active treatment group and the placebo group, at weeks 12 and 24. Post hoc analyses included percentages of patients who reported improvements greater than or equal to minimum clinically important differences and scores greater than or equal to normative values.
Sarilumab in both doses, in combination with csDMARDs, resulted in greater improvements from baseline versus placebo together with csDMARDs:
Among patients who were employed outside the home:
The researchers concluded that, in patients for whom treatment with anti-TNF agents was inadequate or not tolerated, 150-mg and 200-mg doses of sarilumab, given together with csDMARDs, resulted in clinically meaningful patient-reported benefits in terms of pain, fatigue, function, participation, and health status at week 12 and week 24, and that mean changes from baseline translated into clinically meaningful benefits on an individual patient level.
Strand, during a recent Peer Exchange™ panel discussion at The Center for Biosimilars®, said, “In general, I think we’re learning a lot more about the biologic products, and that translates also into learning how we might have better precision medicine—how there might be individual variability and what the appropriate therapy is for a patient. We’re still just cracking that nut, but I think it’s one of the things to look forward to.”
How Vertical Integration Drives Innovation and Access in Biosimilars
December 27th 2024Elie Bahou, PharmD, highlights how vertical integration in the biosimilar industry streamlines costs, improves supply reliability, accelerates market adoption, and enhances patient access, while emphasizing the value of collaboration, quality control, and value-based contracts for sustainable health care delivery.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
13 Strategies to Avoid the Nocebo Effect During Biosimilar Switching
December 18th 2024A systematic review identified 13 strategies, including patient and provider education, empathetic communication, and shared decision-making, to mitigate the nocebo effect in biosimilar switching, emphasizing the need for a multifaceted approach to improve patient perceptions and therapeutic outcomes.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Commercial Payer Coverage of Biosimilars: Market Share, Pricing, and Policy Shifts
December 4th 2024Researchers observe significant shifts in payer preferences for originator vs biosimilar products from 2017 to 2022, revealing growing payer interest in multiple product options, alongside the increasing market share of biosimilars, which contributed to notable reductions in both average sales prices and wholesale acquisition costs.